Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has partnered with the Shanghai Institute of Materia Medica (SIMM) to receive tacit clinical trial approval from the National Medical Products Administration (NMPA) for their antibody drug conjugate (ADC), DS001. The molecule is set to be assessed as a potential treatment for various advanced malignant tumor types.
DS001: An Innovative ADC with VK Linker Technology
The ADC DS001 incorporates Dartsbio’s proprietary VK linker technology and has demonstrated promising tumor inhibitory effects and safety potential in preclinical studies. The drug is anticipated to offer unique therapeutic advantages, particularly in the treatment of pancreatic and gastric cancers, where effective treatment options are often limited.
Commercialization and Financial Arrangements
Dartsbio Pharma retains exclusive rights for the development and commercialization of the drug. The company will lead the advancement into clinical development, with SIMM poised to receive milestone payments and royalties on future sales of DS001. This partnership and the subsequent NMPA approval mark a significant step forward in bringing this innovative treatment to patients in need.-Fineline Info & Tech
